Evidence map›Paper›PMID 29523497›Full record

Observational studyThe Lancet. Infectious diseases2018

Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study.

Peter Okokhere, Andres Colubri, Chukwuemeka Azubike, Christopher Iruolagbe, Omoregie Osazuwa, Shervin Tabrizi, Elizabeth Chin, Sara Asad, Ehi Ediale, Mojeed Rafiu and 15 more

Erratum issuedOpen access · greenAbstract readObservational Study
In one paragraph

Observational study in The Lancet. Infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 90 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 6 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 6 syntheses or guidelines pooled it, 151 citations in OpenAlex.

  1. Pooled it
  2. Clinical Outcomes of Severe Lassa Fever in West Africa: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 9 institutions in 3 countries.

Peter OkokhereDepartment of Medicine, Irrua Specialist Teaching Hospital, Irrua, Nigeria; Institute of Lassa fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria; Department of Medicine, Faculty of Clinical Sciences, Ambrose Alli University, Ekpoma, Edo, Nigeria. Electronic address: okokherep@gmail.com.
Andres ColubriDepartment of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Howard Hughes Medical Institute, Maryland, MD, USA. Electronic address: andres@broadinstitute.org.
Chukwuemeka AzubikeDepartment of Medicine, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
Christopher IruolagbeDepartment of Medicine, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
Omoregie OsazuwaDepartment of Medicine, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
Shervin TabriziBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Elizabeth ChinDepartment of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA; University of California, Los Angeles, CA, USA; Department of Bioinformatics, Los Angeles, CA, USA.
Sara AsadBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Ehi EdialeMassachusetts Institute of Technology, Cambridge, MA, USA.
Mojeed RafiuDepartment of Medicine, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
Donatus AdomehInstitute of Lassa fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
Ikponmwosa OdiaInstitute of Lassa fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
Rebecca AtafoLassa fever Ward, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
Chris AireInstitute of Lassa fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
Sylvanus OkogbeninDepartment of Obstetrics and Gynaecology, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
Meike PahlmanBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Centre for Infection Research, Partner site, Hamburg, Germany.
Beate Becker-ZiajaBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Centre for Infection Research, Partner site, Hamburg, Germany.
Danny AsogunInstitute of Lassa fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
Terrence FradetFathom Information Design, Boston, MA, USA.
Ben FryFathom Information Design, Boston, MA, USA.
Stephen F SchaffnerDepartment of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Harvard School of Public Health, Boston, MA, USA.
Christian HappiDepartment of Biological Sciences and African Center of Excellence for Genomics of Infectious Diseases, Redeemer's University, Edo, Nigeria.
George AkpedeDepartment of Paediatrics, Irrua Specialist Teaching Hospital, Irrua, Nigeria; Department of Paediatrics, Faculty of Clinical Sciences, Ambrose Alli University, Ekpoma, Edo, Nigeria.
Stephan GüntherBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Centre for Infection Research, Partner site, Hamburg, Germany.
Pardis C SabetiDepartment of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Howard Hughes Medical Institute, Maryland, MD, USA; Harvard School of Public Health, Boston, MA, USA.
Irrua Specialist Teaching Hospital · NGBroad Institute · USAmbrose Alli University · NGGerman Center for Infection Research · DEHarvard University · USBernhard Nocht Institute for Tropical Medicine · DEHoward Hughes Medical Institute · USMassachusetts Institute of Technology · USRedeemer's University · NG

Funding

Understanding and controlling antibiotic resistanceU54GM088558 · NIGMS · HARVARD SCHOOL OF PUBLIC HEALTH · PI LIPSITCH, MARC · 2009 to 2018
$26.4M
Utilize Microbial Metagenomics for Viral Pathogen CharacterizationU54HG007480 · NHGRI · REDEEMER'S UNIVERSITY · PI HAPPI, CHRISTIAN T. · 2017 to 2022
$5.5M
Elucidating Genetic Determinants of Resistance to Lassa Hemorrhagic FeverR01AI114855 · NIAID · BROAD INSTITUTE, INC. · PI SABETI, PARDIS CHRISTINE · 2015 to 2019
$3.8M
Host and Microbial Genetic Determinants of Febrile Illness in West AfricaU01HG007480 · NHGRI · REDEEMER'S UNIVERSITY · PI HAPPI, CHRISTIAN T. · 2013 to 2016
$1.6M
Howard Hughes Medical InstituteNHGRI NIH HHS U01 HG007480NHGRI NIH HHS U54 HG007480NIAID NIH HHS R01 AI114855NIGMS NIH HHS U54 GM088558
6 · The paper itself

Abstract

backgroundLassa fever is a viral haemorrhagic disease endemic to west Africa. No large-scale studies exist from Nigeria, where the Lassa virus (LASV) is most diverse. LASV diversity, coupled with host genetic and environmental factors, might cause differences in disease pathophysiology. Small-scale studies in Nigeria suggest that acute kidney injury is an important clinical feature and might be a determinant of survival. We aimed to establish the demographic, clinical, and laboratory factors associated with mortality in Nigerian patients with Lassa fever, and hypothesised that LASV was the direct cause of intrinsic renal damage for a subset of the patients with Lassa fever.

methodsWe did a retrospective, observational cohort study of consecutive patients in Nigeria with Lassa fever, who tested positive for LASV with RT-PCR, and were treated in Irrua Specialist Teaching Hospital. We did univariate and multivariate statistical analyses, including logistic regression, of all demographic, clinical, and laboratory variables available at presentation to identify the factors associated with patient mortality.

findingsOf 291 patients treated in Irrua Specialist Teaching Hospital between Jan 3, 2011, and Dec 11, 2015, 284 (98%) had known outcomes (died or survived) and seven (2%) were discharged against medical advice. Overall case-fatality rate was 24% (68 of 284 patients), with a 1·4 times increase in mortality risk for each 10 years of age (p=0·00017), reaching 39% (22 of 57) for patients older than 50 years. Of 284 patients, 81 (28%) had acute kidney injury and 104 (37%) had CNS manifestations and thus both were considered important complications of acute Lassa fever in Nigeria. Acute kidney injury was strongly associated with poor outcome (case-fatality rate of 60% [49 of 81 patients]; odds ratio [OR] 15, p<0·00001). Compared with patients without acute kidney injury, those with acute kidney injury had higher incidence of proteinuria (32 [82%] of 39 patients) and haematuria (29 [76%] of 38) and higher mean serum potassium (4·63 [SD 1·04] mmol/L) and lower blood urea nitrogen to creatinine ratio (8·6 for patients without clinical history of fluid loss), suggesting intrinsic renal damage. Normalisation of creatinine concentration was associated with recovery. Elevated serum creatinine (OR 1·3; p=0·046), aspartate aminotransferase (OR 1·5; p=0·075), and potassium (OR 3·6; p=0·0024) were independent predictors of death.

interpretationOur study presents detailed clinical and laboratory data for Nigerian patients with Lassa fever and provides strong evidence for intrinsic renal dysfunction in acute Lassa fever. Early recognition and treatment of acute kidney injury might significantly reduce mortality.

fundingGerman Research Foundation, German Center for Infection Research, Howard Hughes Medical Institute, US National Institutes of Health, and World Bank.

Indexed as

AdultCohort StudiesFemaleHumansLassa FeverLogistic ModelsMaleMultivariate AnalysisNigeriaRetrospective StudiesTreatment Outcome

Identifiers

PMID29523497
PMCPMC5984133
OpenAlexW2794169242

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.